INS and type 2 diabetes mellitus: Our findings were in line with a previous observation suggesting that the use of rapid-acting insulin analogue glulisine could be associated with a risk reduction of 24% for macrovascular events in patients with type 2 diabetes as compared with the use of human regular insulin [12].